How Taiwan Integrates Semiconductors and AI to Power the Future of Precision Health
Dr. Pan-Chyr Yang Outlines Why Keeping the Healthy Well Beats Treating the Sick—and How Taiwan’s Tech Ecosystem is Architecting the Shift
At the recent 2026 MIT ILP-Epoch Taiwan Symposium—centered on the convergence of semiconductors, healthcare, and physical AI—Taiwan’s world-renowned lung cancer genomics expert delivered a comprehensive account of how Taiwan leverages its semiconductor and AI in medical services, as well as sharing his compelling vision for the future of medicine.
Serving as the President of the Institute for Biotechnology and Medicine Industry (IBMI), Dr. Pan-Chyr Yang is an Academician at Academia Sinica and a renowned clinician-scientist who previously served as the President of National Taiwan University (NTU) and Dean of the NTU College of Medicine. His pioneering translational research on lung cancer genomics—specifically identifying the distinct molecular and environmental risk factors driving lung cancer in East Asian non-smokers—fundamentally reshaped regional oncology frameworks and directly inspired Taiwan’s national screening policies.
At the symposium, Dr. Yang’s core message was clear: the healthcare industry must pivot from treating the sick to keeping the healthy from falling ill.
“As a clinician, most of the time when patients come, they already have symptoms... This is the tip of the iceberg,” Dr. Yang noted. “The most important part is the iceberg under the sea level. Can we identify the risk of the healthy population and practice precision prevention, precision screening, and health promotion? Precision health is even more important than precision medicine.”
IBMI: Architecting Taiwan’s Bio-Design
Steering this paradigm shift is IBMI, an organization founded in 2002 to rapidly advance national health by scaling Taiwan’s biotech and medical sectors. Today, IBMI operates as a premier cross-disciplinary ecosystem architect, uniquely uniting heads of top medical centers, tech and semiconductor executives, and biotech innovators. By sitting at the absolute convergence point of Information Communications Technologies (ICT), silicon foundry manufacturing, and clinical science, the institute spearheads software-driven, AI-assisted biomedical R&D—essentially working to replicate the global scale and supply-chain relevance of Taiwan’s semiconductor industry within the healthcare sector.
Powered by Silicon: The Semiconductor Foundation of Precision Health
A central theme of Dr. Yang’s address was Taiwan’s unique capability to leverage its semiconductor dominance to revolutionize global healthcare. While the global healthcare market is projected to skyrocket from US$11 trillion in 2025 to nearly US$50 trillion by the 2030s, unlocking this value requires unprecedented computational infrastructure.
“Global AI hardware today is powered by Taiwan,” Dr. Yang emphasized, pointing to the nation’s complete AI hardware ecosystem that spans IC design, silicon manufacturing, advanced packaging (such as CoWoS), component modules, and system applications. Taiwan’s strategy relies on a powerful triad: Data, Science, and Silicon.
By merging advanced semiconductor fabrication with massive healthcare data, Taiwan is moving beyond theoretical AI models. It is deploying high-performance silicon to process multi-omics, run complex polygenic risk algorithms, and drive edge-AI medical devices—essentially transforming preventative health from an abstract concept into a scalable, high-throughput infrastructure.
Turning Data into Precision Screening
The true engine behind Taiwan’s precision health initiative is its rich, longitudinal data repository. The National Health Insurance (NHI) system covers 99.9% of the population and has accumulated comprehensive records for over 25 years. When paired with biobanks and advanced computing, this data is yielding historic breakthroughs:
The Non-Smoking Lung Cancer Paradigm: Lung cancer is the leading cause of cancer mortality worldwide, yet an anomalously high number of East Asian women develop it despite having no history of smoking. Through multi-omics research, Taiwanese scientists identified specific endogenous and exogenous risk factors, leading the government to launch a landmark low-dose CT (LDCT) screening program in July 2022 that has already screened over 250,000 at-risk individuals.
The TPMI Powerhouse: Launched in 2019 by Academia Sinica across 33 hospitals, the Taiwan Precision Medicine Initiative (TPMI) has recruited over 560,000 participants. By matching genomic profiles with electronic medical records (EMR), TPMI has developed Polygenic Risk Scores (PRS) for over 250 common diseases—including hypertension, type 2 diabetes, and chronic kidney disease. Crucially, this fills a massive gap in global medicine, where genomic data has historically skewed heavily toward European ancestry.
Making the Invisible Visible: AI Medical Devices in Action
Taiwan’s tech-meets-med ecosystem has already yielded 139 AI medical devices approved by the TFDA, 38 of which have also cleared the US FDA. Dr. Yang highlighted three standout case studies during his keynote:
1. AI-Enabled Electrocardiography (ECG)
Developed by the National Defense Medical University in collaboration with Quanta Computer, this platform uses a simple, non-invasive ECG to accurately predict a patient’s gender, age, BMI, renal function, electrolyte levels, and even hemoglobin levels without a blood draw. A randomized controlled trial published in Nature Medicine confirmed that this AI-enabled ECG significantly reduces all-cause mortality by predicting impending cardiac arrest and early myocardial infarction, allowing clinicians to intervene early.
2. Digital Pathology Workflow (Ether AI)
Now deployed in major institutions like National Taiwan University Hospital and various centers across Germany and Japan, Ether AI automates immunohistochemistry quantification. Instead of manual counting, the AI precisely calculates PD-1 expression in cancer cells, detects lymph node metastasis, and differentiates complex leukemia and lymphoma cells instantly.
3. Population Screening via Standard Imagery (Acer Medical)
By utilizing a standard, routine chest X-ray, Acer Medical’s AI algorithm can detect osteoporosis on the spot, bypassing the need for specialized bone density scans (densitometry) and enabling early therapeutic intervention.
The Next Frontier: Overcoming Borders via Federated Learning
Despite these localized successes, Dr. Yang was candid about the roadblocks Taiwan must overcome to scale globally, particularly regulatory fragmentation and cross-border data privacy. Because health data is strictly regulated and highly sensitive, sharing raw datasets across borders remains a legal and ethical bottleneck.
To unlock the next phase of precision health, Dr. Yang outlined Taiwan’s infrastructure roadmap:
Federated Learning Platforms: To train AI models globally without compromising patient privacy, data will remain strictly siloed within individual hospitals. Instead, the AI models themselves will travel to the data, learning and refining their algorithms locally before aggregating the insights.
Interoperable EMRs: Standardizing and accelerating medical record exchanges to create fluid, unified applications.
Algorithmic Reimbursement: Convincing governments and single-payer systems to officially reimburse AI diagnostics to institutionalize these lifelines into daily clinical workflows.
“Taiwan has committed to turning data, science, and semiconductors into the foundation of precision health for all,” Dr. Yang concluded, extending an invitation for cross-border cooperation. “It is not a single country that can solve this alone. It takes global collaboration.”
Great research efforts. We hope to make it available cross national boundaries, by sharing big data and yet keep personal information confidential.🤗